|View printer-friendly version|
Histogenics Corporation Announces Approval of Merger by Stockholders at Special Meeting
The proposed merger remains subject to further customary closing conditions and regulatory approvals.
Upon closing of the transaction, the combined company will change its name to “Ocugen, Inc.” and the Nasdaq trading symbol will become “OCGN.” The executive team of Ocugen will serve as the executive team of the combined company, led by Shankar Musunuri, Ph.D., M.B.A., as Chairman, Chief Executive Officer and Co-Founder.
Ocugen is a clinical stage biopharmaceutical company focused on discovering, developing and commercializing a pipeline of innovative therapies that address rare and underserved eye diseases.
The final voting results for Histogenics’ special meeting of stockholders will be filed with the
Additional Information about the Proposed Merger and Where to Find It
In connection with the proposed Merger,
No Offer or Solicitation
This communication shall not constitute an offer to sell or the solicitation of an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offering of securities in connection with the proposed Merger shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended.
Participants in the Solicitation
This Press Release contains forward-looking statements based upon Histogenics’ current expectations. Forward-looking statements involve risks and uncertainties, and include, but are not limited to, statements about the expected final results of the voting of Histogenics’ stockholders at the special meeting, the structure, timing and completion of the proposed Merger, the financing contemplated to occur prior to the Merger and the sale of certain assets of Histogenics’ following the Merger; expectations regarding Nasdaq’s delisting and hearing processes, Histogenics’ prospects to regain compliance with Nasdaq’s continuing listing standards and remain listed on The
Contact: Investor Relations: Tel: (781) 312-5013 InvestorRelations@histogenics.com
Source: Histogenics Corporation